Stockreport

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

Pulmonx Corporation  (LUNG) 
US:NASDAQ Investor Relations: investor.prolunginc.com/investor-relations
PDF AeriSeal System Shows Promise in Limiting Collateral Ventilation, Potentially Enabling a Greater Number of Severe COPD/Emphysema Patients to Benefit from Treatment with [Read more]